Anatomical heterogeneity of residual disease in chronic lymphocytic leukemia treated with ibrutinib

Hematol Oncol. 2022 Dec;40(5):1105-1108. doi: 10.1002/hon.3039. Epub 2022 Jun 8.

Adalgisa Condoluci^{1

2}, Lisa Milan³, Gabriela Forestieri², Lodovico Terzi di Bergamo², Valeria Spina², Alessio Bruscaggin², Clara Deambrogi⁴, Riccardo Moia⁴, Marina Deodato⁵, Gaby Fahrni⁶, Roberta Mattarucchi⁷, Michele Merli⁷, Bernhard Gerber^{1

8}, Georg Stussi^{1

9}, Francesco Passamonti⁷, Michael Gregor⁶, Alessandra Tedeschi⁵, Gianluca Gaidano⁴, Davide Rossi^{1

2

9}, Luca Ceriani^{3

9}

¹ Clinic of Hematology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
² Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland.
³ Clinic for Nuclear Medicine and Molecular Imaging, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.
⁴ Department of Translational Medicine, Division of Hematology, University of Eastern Piedmont, Novara, Italy.
⁵ Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
⁶ Division of Hematology, Cantonal Hospital of Lucerne, Lucerne, Switzerland.
⁷ Ospedale di Circolo of Varese & Department of Medicine and Surgery, Hematology, University of Insubria, Varese, Italy.
⁸ University of Zurich, Zurich, Switzerland.
⁹ Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.

No abstract available

Publication types